Terns Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver…

Biotechnology
US, Foster City [HQ]
Major Shareholders · Proxy Ben. Owners

Shareholders

Breakdown
Institutional
Insider
Retail
97.76%
0.15%
2.09%
Intraday
Shares Outstanding
84,938,900
Volume
706,210
Volume on Avg.
1,634,862
Beneficial Owners Beta
SEC Source
Owner Shares Equivalence - $4.67 per share Last Form/Filing Last Transaction
10% Holder
- No data -
Officers/Directors Below 10%
- No data -
End of TERN's Analysis
CIK: 1831363 CUSIP: 880881107 ISIN: US8808811074 LEI: - UEI: -
Secondary Listings
TERN has no secondary listings inside our databases.